Wed. 28 Feb 2024, 7:02am ET
Benzinga
Earnings, News
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 63.64 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $10.70 million which missed the analyst consensus estimate of $14.77 million by 27.55 percent. This is a 27.14 percent decrease over sales of $14.69 million the same period last year.